市場調查報告書

α-抗胰蛋白酶缺乏症:市場考察,流行病學,市場預測

Alpha-Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 453798
出版日期 內容資訊 英文 146 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
α-抗胰蛋白酶缺乏症:市場考察,流行病學,市場預測 Alpha-Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年09月01日內容資訊: 英文 146 Pages
簡介

本報告提供全球α-抗胰蛋白酶缺乏症 (AATD) 治療藥的市場相關分析,疾病概要和目前治療手法/演算法,新的治療藥的開發、上市的動向,主要產品的銷售額、市場佔有率預測,全球整體及主要國家 (美國、歐洲各國、日本)的市場趨勢 (總計12年份),主要的推動及阻礙市場要素,目前未滿足需求,潛在的市場機會等相關調查。

第1章 簡介

第2章 α-抗胰蛋白酶缺乏症:市場概要

  • 市場佔有率結構 (最新值、預測值)

第3章 疾病的背景情況和概要:α-抗胰蛋白酶缺乏症

  • 簡介
  • 症狀
  • 病因
  • 風險要素
  • α-抗胰蛋白酶缺乏症的遺傳
  • 病理生理學
  • 併發症
  • 診斷
  • 治療
  • 診斷延遲

第4章 流行病學和患者人口

  • (6MM)的α-抗胰蛋白酶缺乏症主要6個國家的患病人數
  • (7MM)的α-抗胰蛋白酶缺乏症主要7個國家的患病人數:各地區
  • (6MM)的α-抗胰蛋白酶缺乏症主要6個國家的患病人數:分佈情形 (最新值)
  • (6MM)的α-抗胰蛋白酶缺乏症主要6個國家的患病人數:分佈情形 (預測值)
  • α-抗胰蛋白酶缺乏症的流行病學:各國
    • 美國
    • (EU5歐洲主要5個國家)
    • 日本

第5章 治療的演算法

  • 如果併發α-抗胰蛋白酶缺乏症的管理方法:肺病
  • 如果併發α-抗胰蛋白酶缺乏症的管理方法:肝臟病

第6章 未滿足需求

第7章 已上市醫藥品

第8章 新治療藥

第9章 α-抗胰蛋白酶缺乏症 (AATD):全球市場分析

  • 全球市場規模
  • 已上市產品的市場佔有率:全球市場
  • 已上市產品的銷售額:全球市場
  • α-抗胰蛋白酶缺乏症的治療中的患者人口

第10章 α-抗胰蛋白酶缺乏症 (AATD):各國市場分析

  • 美國
    • α-抗胰蛋白酶缺乏症的市場規模
    • 已上市產品的市場佔有率
    • 已上市產品的銷售額
    • α-抗胰蛋白酶缺乏症的治療中的患者人口
  • (EU5歐洲主要5個國家)
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 其他的國家 (RoW)

第11章 Grifols對α-抗胰蛋白酶缺乏症治療藥開發的配合措施

第12章 USFDA (美國食品藥物管理局)對α-抗胰蛋白酶缺乏症患者的配合措施

第13章 推動市場要素

第14章 阻礙市場要素

第15章 附錄

第16章 分析方法

  • 利用之資訊來源

第17章 諮詢服務

第18章 免責聲明

第19章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0001

DelveInsight's 'Alpha- Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of AATD from 2017 to 2028 segmented by the US, EU-5 countries and Rest of the World (RoW). The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2017-2028

Alpha- Antitrypsin Deficiency (AATD) - Disease Understanding and Treatment Algorithm

The DelveInsight Alpha- Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for AATD in the US, Europe, and Japan.

Alpha- Antitrypsin Deficiency (AATD) Epidemiology

The AATD epidemiology division provide the insights about historical and current patient pool and forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented into two parts: Population at the risk of developing AATD on the basis of allele [PiSS, PiSZ, PiZZ) and Prevalent cases of AATD in 6 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)]. As AATD is quite rare in Japan, the report features the diagnosed population of AATD in Japan.

According to DelveInsight, the prevalent cases of AATD was 235,500 in 2017 in 6MM and, is expected to increase during the study period i.e., 2017-2028. Among 6MM, United States account for highest prevalent cases of AATD with almost 100,000 prevalent cases in 2017. Among the EU5 countries, Germany has the highest prevalent population of AATD with, followed by United Kingdom, which has prevalent population of 27,930 in 2017.

Alpha- Antitrypsin Deficiency (AATD) Drug Chapters

This segment of the AATD report encloses the detailed analysis of marketed drugs and late stage pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

AATD is rare disease which is highly under diagnosed and treated by the augmentation therapy products. United States Food and Drug Administration (FDA) has approved four augmentation therapies till date Prolastin-C (Grifols), Aralast NP (Shire), Zemaira (CSL Behring) and Glassia (Kamada Ltd.) and more potential therapies are on the horizon. This report includes detailed chapters of marketed products along with the promising upcoming therapies.

Alpha- Antitrypsin Deficiency (AATD) Market Outlook

The AATD market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The report provides global market share of AATD i.e., 6 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Rest of World (RoW). In 2017, market size of AATD was USD 992 million.

The region-wise market size for AATD in US, EU-5 countries (Germany, France, Italy, Spain and the U.K.) and Rest of the World (RoW) shows highest market size in US, followed by Germany, the lowest being in the UK due to the difference of opinion between regulatory authorities and the manufacturer companies owing to the reimbursement policies.

Alpha- Antitrypsin Deficiency (AATD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alpha- Antitrypsin Deficiency (AATD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alpha- Antitrypsin Deficiency (AATD) Report Key Strengths

  • 10 Year Forecast
  • 6MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Alpha- Antitrypsin Deficiency (AATD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the AATD market
  • Organize sales and marketing efforts by identifying the best opportunities for AATD market
  • To understand the future market competition in the AATD market

Table of Contents

1. Report Introduction

2. Alpha Antitrypsin Deficiency Market Overview at a Glance

  • 2.1. Market Share Distribution of Alpha Antitrypsin Deficiency in 2017
  • 2.2. Market Share Distribution of Alpha Antitrypsin Deficiency in 2028

3. Disease Background and Overview: Alpha Antitrypsin Deficiency

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Genetic Inheritance of Alpha Antitrypsin Deficiency
  • 3.6. Pathophysiology
  • 3.7. Complications
  • 3.8. Diagnosis
  • 3.9. Treatment
  • 3.10. Diagnostic Delay

4. Epidemiology and Patient Population

  • 4.1. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM
  • 4.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - By Region
  • 4.3. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - Distribution (2017)
  • 4.4. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - Distribution (2028)
  • 4.5. Epidemiology of Alpha-1-Antitrypsin Deficiency- By Country
    • 4.5.1. United States
      • 4.5.1.1. Assumptions and Rationale
      • 4.5.1.2. Population at risk of Alpha Antitrypsin Deficiency in United States
      • 4.5.1.3. Prevalent Population of Alpha Antitrypsin Deficiency in Unites States
      • 4.5.1.4. Diagnosed Prevalent Population of AATD in The United States
      • 4.5.1.5. Gender- Specific Prevalent Population of AATD in The United States
      • 4.5.1.6. Comorbidities associated with AATD in The United States
    • 4.5.2. EU5
      • 4.5.2.1. Assumptions and Rationale
      • 4.5.2.2. Germany
      • 4.5.2.2.1. Population at risk of Alpha Antitrypsin Deficiency in Germany
      • 4.5.2.2.2. Prevalent Population of Alpha Antitrypsin Deficiency in Germany
      • 4.5.2.2.3. Diagnosed Prevalent Population of AATD in Germany
      • 4.5.2.2.4. Gender- Specific Prevalent Population of AATD in Germany
      • 4.5.2.2.5. Comorbidities associated with AATD in Germany
      • 4.5.2.3. France
      • 4.5.2.3.1. Population at risk of Alpha Antitrypsin Deficiency in France
      • 4.5.2.3.2. Prevalent Population of Alpha Antitrypsin Deficiency in France
      • 4.5.2.3.3. Diagnosed Prevalent Population of AATD in France
      • 4.5.2.3.4. Gender- Specific Prevalent Population of AATD in France
      • 4.5.2.3.5. Comorbidities associated with AATD in France
      • 4.5.2.4. Italy
      • 4.5.2.4.1. Population at risk of Alpha Antitrypsin Deficiency in Italy
      • 4.5.2.4.2. Prevalent Population of Alpha Antitrypsin Deficiency in Italy
      • 4.5.2.4.3. Diagnosed Prevalent Population of AATD in Italy
      • 4.5.2.4.4. Gender- Specific Prevalent Population of AATD in Italy
      • 4.5.2.4.5. Comorbidities associated with AATD in Italy
      • 4.5.2.5. Spain
      • 4.5.2.5.1. Population at risk of Alpha Antitrypsin Deficiency in Spain
      • 4.5.2.5.2. Prevalent Population of Alpha Antitrypsin Deficiency in Spain
      • 4.5.2.5.3. Diagnosed Prevalent Population of AATD in Spain
      • 4.5.2.5.4. Gender- Specific Prevalent Population of AATD in Spain
      • 4.5.2.5.5. Comorbidities associated with AATD in Spain
      • 4.5.2.6. United Kingdom
      • 4.5.2.6.1. Population at risk of Alpha Antitrypsin Deficiency in UK
      • 4.5.2.6.2. Prevalent Population of Alpha Antitrypsin Deficiency in UK
      • 4.5.2.6.3. Diagnosed Prevalent Population of AATD in The UK
      • 4.5.2.6.4. Gender- Specific Prevalent Population of AATD in The UK
      • 4.5.2.6.5. Comorbidities associated with AATD in The UK
    • 4.5.3. Japan
      • 4.5.3.1. Diagnosed Population of Alpha Antitrypsin Deficiency in Japan

5. Treatment Algorithm

  • 5.1. Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
  • 5.2. Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

6. Unmet Needs

7. Marketed Drugs

  • 7.1. Prolastin C: Grifols
    • 7.1.1. Drug Description
    • 7.1.2. Mechanism of Action
    • 7.1.3. Regulatory Milestones
    • 7.1.4. Advantages & Disadvantages
    • 7.1.5. Product Profile
    • 7.1.6. Safety and Efficacy of Prolastin-C
  • 7.2. Glassia: Kamada
    • 7.2.1. Drug Description
    • 7.2.2. Mechanism of Action
    • 7.2.3. Regulatory Milestones
    • 7.2.4. Advantages & Disadvantages
    • 7.2.5. Safety and Efficacy of Glassia
    • 7.2.6. Product Profile
  • 7.3. Aralast: Shire
    • 7.3.1. Drug Description
    • 7.3.2. Mechanism of Action
    • 7.3.3. Regulatory Milestones
    • 7.3.4. Advantages & Disadvantages
    • 7.3.5. Safety and Efficacy of Aralast
    • 7.3.6. Product Profile
  • 7.4. Zemaira: CSL Behring
    • 7.4.1. Drug Description
    • 7.4.2. Mechanism of Action
    • 7.4.3. Regulatory Milestones
    • 7.4.4. Advantages & Disadvantages
    • 7.4.5. Safety and Efficacy of Zemaira
    • 7.4.6. Product Profile
  • 7.5. Alfalastin: LFB Biotechnologies
    • 7.5.1. Description
    • 7.5.2. Regulatory Milestones
    • 7.5.3. Advantages and Disadvantages
    • 7.5.4. Product Profile
    • 7.5.5. Safety and Efficacy
    • 7.5.6. Side effects
  • 7.6. Trypsone: Grifols
  • 7.7. Description
  • 7.8. Regulatory Milestones
  • 7.9. Advantages and Disadvantages
  • 7.10. Product Profile
  • 7.11. Efficacy and Safety
  • 7.12. Side effects

8. Emerging Therapies

  • 8.1. Inhaled AAT (Glassia IH): Kamada Ltd.
  • 8.2. Regulatory Milestones
  • 8.3. Product Development Activities
  • 8.4. Clinical Development
  • 8.5. Product Profile

To be continued in report

9. Alpha Antitrypsin Deficiency: Global Market Analysis

  • 9.1. Global Market Size of AATD
  • 9.2. Global Percentage Share of drugs marketed for AATD
  • 9.3. Global Market Sales of AATD by Products
  • 9.4. Global Treated Population for AATD

10. Alpha Antitrypsin Deficiency: Country-Wise Market Analysis

  • 10.1. United States
    • 10.1.1. Market Size of AATD in The United States
    • 10.1.2. Total Market Size of AATD The United States
    • 10.1.3. Market Sale of Alpha Antitrypsin Deficiency by Therapies in The United States
  • 10.2. EU-5
    • 10.2.1. Germany
      • 10.2.1.1. Market Size of AATD in Germany
      • 10.2.1.2. Total Market Size of AATD Germany
      • 10.2.1.3. Market Sale of Alpha Antitrypsin Deficiency by Therapies in Germany
    • 10.2.2. France
      • 10.2.2.1. Market Size of AATD in France
      • 10.2.2.2. Total Market Size of AATD France
      • 10.2.2.3. Market Sale of Alpha Antitrypsin Deficiency by Therapies in France
    • 10.2.3. Italy
      • 10.2.3.1. Market Size of AATD in Italy
      • 10.2.3.2. Total Market Size of AATD Italy
      • 10.2.3.3. Market Sale of Alpha Antitrypsin Deficiency by Therapies in Italy
    • 10.2.4. Spain
      • 10.2.4.1. Market Size of AATD in Spain
      • 10.2.4.2. Total Market Size of AATD Spain
      • 10.2.4.3. Market Sale of Alpha Antitrypsin Deficiency by Therapies in Spain
    • 10.2.5. United Kingdom
      • 10.2.5.1. Market Size of AATD in The UK
      • 10.2.5.2. Total Market Size of AATD The UK
      • 10.2.5.3. Market Sale of Alpha Antitrypsin Deficiency by Therapies in The UK
  • 10.3. Rest of the World (RoW)

11. Grifols Initiatives towards Alpha Anti-trypsin deficiency

12. USFDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

13. Market Drivers

14. Market Barriers

15. Appendix

16. Report Methodology

  • 16.1. Sources Used

17. Consulting Services

18. Disclaimer

19. About DelveInsight

List of Tables

  • TABLE 1: DIAGNOSTIC DELAY INTERVAL FOR AATD
  • TABLE 2: TOTAL PREVALENT POPULATION OF ALPHA-1-ANTITRYPSIN DEFICIENCY IN 6 MM (2017-2028)
  • TABLE 3: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 4: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 5: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 6: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 7: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 8: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 9: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 10: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 11: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 12: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 13: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 14: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 15: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 16: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 17: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 18: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 19: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 20: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 21: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 22: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 23: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 24: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 25: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 26: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 27: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 28: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED KINGDOM (2017-2028)
  • TABLE 29: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED KINGDOM (2017-2028)
  • TABLE 30: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • TABLE 31: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • TABLE 32: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • TABLE 33: DIAGNOSED POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN JAPAN (2017-2028)
  • TABLE 34: ALN-AAT02, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 35: ARO-AAT, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 36: VX-814, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 37: VX-864, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 38: CARBAMAZEPINE, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 39: ALVELESTAT, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 40: INBRX-101, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 41: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD MILLION (2017 -2028)
  • TABLE 42: TOTAL MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • TABLE 43: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD MILLION (2017 -2028)
  • TABLE 44: US MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • TABLE 45: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD MILLION (2017 -2028)
  • TABLE 46: GERMANY MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • TABLE 47: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD MILLION (2017 -2028)
  • TABLE 48: FRANCE MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • TABLE 49: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD MILLION (2017 -2028)
  • TABLE 50: ITALY MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • TABLE 51: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD MILLION (2017 -2028)
  • TABLE 52: SPAIN MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • TABLE 53: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD MILLION (2017 -2028)
  • TABLE 54: UK MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • TABLE 55: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD MILLION (2017 -2028)
  • TABLE 56: ROW MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)

List of Figures

  • FIGURE 1: RISK FACTORS FOR AATD
  • FIGURE 2: RISK FACTORS FOR AATD
  • FIGURE 3: RISK FACTORS FOR AATD
  • FIGURE 4: ALPHA-1 ANTITRYPSIN BINDS AND INACTIVATES NEUTROPHIL ELASTASE.
  • FIGURE 5: PATHOGENESIS OF ALPHA ANTITRYPSIN DEFICIENCY
  • FIGURE 6: DIAGNOSTIC ALGORITHM OF ALPHA ANTITRYPSIN DEFICIENCY
  • FIGURE 7: GENERAL TREATMENT OF ALPHA ANTITRYPSIN DEFICIENCY
  • FIGURE 8: STRATEGIES FOR DELIVERY OF ENGINEERED NUCLEASES: A) EX-VIVO ; B) IN VIVO
  • FIGURE 9:GENOME EDITING WITH ENGINEERED NUCLEASES
  • FIGURE 10: TOTAL PREVALENT POPULATION OF ALPHA-1-ANTITRYPSIN DEFICIENCY IN 6 MM (2017-2028)
  • FIGURE 11: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 12: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 13: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 14: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 15: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 16: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 17: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 18: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 19: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 20: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 21: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 22: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 23: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 24: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 25: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 26: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 27: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 28: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 29: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 30: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 31: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN ( (2017-2028)
  • FIGURE 32: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • FIGURE 33: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • FIGURE 34: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • FIGURE 35: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • FIGURE 36: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED KINGDOM (2017-2028)
  • FIGURE 37: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED KINGDOM (2017-2028)
  • FIGURE 38: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • FIGURE 39: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • FIGURE 40: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • FIGURE 41: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN JAPAN (2017-2028)
  • FIGURE 42: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2028)
  • FIGURE 43: TOTAL MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY THERAPIES IN USD, MILLION (2017 -2028)
  • FIGURE 44: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2028)
  • FIGURE 45: US MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • FIGURE 46: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2028)
  • FIGURE 47: GERMANY MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • FIGURE 48: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2028)
  • FIGURE 49: FRANCE MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • FIGURE 50: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2028)
  • FIGURE 51: ITALY MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • FIGURE 52: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2028)
  • FIGURE 53: SPAIN MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • FIGURE 54: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2028)
  • FIGURE 55: UNITED KINGDOM MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • FIGURE 56: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2028)
  • FIGURE 57: ROW MARKET SALES OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2028)
  • FIGURE 58: MARKET DRIVERS
  • FIGURE 59:MARKET BARRIERS
Back to Top